Yan Liang

Prof. Dr. Yan Liang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2021 in European Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
QYQing Yang
Qing Yang
XLXinyue Lang
Xinyue Lang
WLWei Li
Wei Li
YLYan Liang
Yan Liang

14 April 2020 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
YLYan Liang
Yan Liang
JZJun Zhu
Jun Zhu
LLLisheng Liu
Lisheng Liu
SASonia S Anand
Sonia S Anand
SCStuart J Connolly
Stuart J Connolly
FIfor the COMPASS Investigators
for the COMPASS Investigators
The COMPASS trial demonstrated that the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease or peripheral artery disease by 24% during a mean follow-up of 23 months. We explored whether this effect varies by sex. The effects were examined in women and men using log-rank tests and Kaplan–Meier curve. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were obtained from stratified Cox proportional hazards models to explore subgroup effects including subgroup of women and men according to baseline modified REACH risk score. Of 27 395 patients randomized, 18 278 were allocated to receive rivaroxaban plus aspirin (n = 9152) or aspirin alone (n = 9126), and of these, 22.1% were women. Women compared with men had similar incidence rates for MACE and major bleeding but borderline lower rates for myocardial infarction (1.7% vs. 2.2%, P = 0.05). The effect of combination therapy compared with aspirin in women and men was consistent for MACE (women: 3.8% vs. 5.2%, HR 0.72, 95% CI 0.54–0.97; men: 4.2% vs. 5.5%, HR 0.76, 95% CI 0.66–0.89; P interaction 0.75) and major bleeding (women: 3.1% vs. 1.4%, HR 2.22, 95% CI 1.42–3.46; men: 3.2% vs. 2.0%, HR 1.60, 95% CI 1.29–1.97; P interaction 0.19). There was no significant interaction between randomized treatment and baseline modified REACH score above or below the median for MACE or major bleeding. In patients with stable coronary artery disease or peripheral artery disease, the combination of rivaroxaban (2.5 mg twice daily) and aspirin compared with aspirin alone appears to produce consistent benefits in women and men, independent of baseline cardiovascular risk.

15 August 2018 in Clinical Hypertension
Verified
Journal Article
Open access
PDF file
MLMingming Liu
Mingming Liu
YLYan Liang
Yan Liang
JZJun Zhu
Jun Zhu
YYYanmin Yang
Yanmin Yang
WMWenfang Ma
Wenfang Ma
GZGuozheng Zhang
Guozheng Zhang
Data are limited with regard to the relationship of albuminuria and major adverse cardiovascular events (MACE) in Chinese elder patients with high cardiovascular risk. We did a retrospective cohort study using Chinese elder patients with high cardiovascular risks (n = 1474) to identify the association of albumin-to-creatinine ratio (ACR) and the incidence of MACE and all-cause mortality. Individuals were followed up from January, 2002 to November, 2007. The all-cause mortality and MACE, composite outcome of cardiovascular death, myocardial infarction, stroke and hospitalization of congestive heart failure were defined as primary endpoint. During the median following up of 56 months, 213 patients developed primary endpoint and 117 patients died. Patients with higher baseline urinary ACR (> 30 mg/g) experienced a nearly 2-fold of all-cause mortality and a 3-fold of heart failure hospitalization than those with lower baseline urinary ACR (≤10 mg/g).MACE, cardiovascular death, stoke and myocardial infarction showed no difference in three grades of urinary ACR (> 30 mg/g, 10 mg/g-30 mg/g, ≤10 mg/g) in this cohort. Patients above 65 years with increased ACR tended to experience higher mortality risks, and the association of increased ACR with higher hospitalization of congestive heart failure seemed to be more prominent in patients below 65 years than above 65 years. In this post hoc analysis of Chinese individuals with high cardiovascular risks, higher urinary ACR was associated with higher all-cause mortality and heart failure hospitalization. Further studies are needed to find out whether there is age-specific ACR cutoff point.

1 May 2023 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
QYQing Yang
Qing Yang
XQXin Quan
Xin Quan
CWChuangshi Wang
Chuangshi Wang
LYLitian Yu
Litian Yu
YYYanmin Yang
Yanmin Yang
YLYan Liang
Yan Liang
Background: It remains unknown whether anticoagulation for persistent left ventricular (LV) thrombus should be continued indefinitely. Identifying patients with a high risk of thrombus unresolved may be helpful to determine the optimum anticoagulation duration. This study aimed to develop a prediction model to forecast thrombus persistence or recurrence in patients with LV thrombus. Methods: We enrolled patients prospectively from 2020 to 2022 and retrospectively from 2013 to 2019 at the National Center of Cardiovascular Diseases of China. The two cohorts were then combined to derive predictive models of thrombus persistence/recurrence. The primary study comprised patients who received systemic oral anticoagulants and had imaging records available at the end of a 3-month follow-up period. The Lasso regression algorithm and the logistic regression were performed to select independent predictors. The calibration curve was generated and a nomogram risk prediction model was applied as a risk stratification tool. Results: A total of 172 (64 in the prospective cohort and 108 in the retrospective cohort) patients were included, with 124 patients in a training set and 48 patients in a validation set. Six predictors were incorporated into the multivariate logistic regression prediction model. The area under the receiving operating characteristic was 0.852 in the training set and 0.631 in the validation set. Patients with protuberant thrombus and higher baseline D-dimer levels had a reduced risk of persistence/recurrence (OR 0.17, 95% CI 0.03–0.69, P = 0.025; OR 0.67, 95% CI 0.43–0.91, P = 0.030, separately), whereas thicker thrombus was linked to an increased rate of persistent thrombus (OR 1.11, 95% CI 1.05–1.20, P = 0.002). Additionally, patients with diverse diagnoses or receiving different antiplatelet treatments had different rates of LV thrombus persistence/recurrence at 3 months. Conclusions: This prediction model provides tools to forecast the occurrence of persistent/recurrent thrombus and allows the identification of characteristics associated with unresolved thrombus. To validate the model and determine the duration of anticoagulation in patients with persistent thrombus, prospective randomized trials are necessary.

1 January 2022 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
QYQing Yang
Qing Yang
XLXinyue Lang
Xinyue Lang
XQXin Quan
Xin Quan
ZGZebin Gong
Zebin Gong
YLYan Liang
Yan Liang
Aim of the Study. To evaluate the utilization of oral antithrombotic agents, non‐vitamin K antagonist oral anticoagulants (NOACs), vitamin K antagonists (VKAs), or antiplatelet therapy (APT), in ventricular thrombus (VT) patients and to analyze factors for thrombus resolution and clinical outcomes. Methods. This retrospective observational study was conducted from 2010 to 2019 in National Center of Cardiovascular Diseases of China. We included patients with VT confirmed by imaging. The primary outcome was the rate of thrombus resolution. Hazard ratio (HR) was calculated with or without adjustment for covariates using Cox proportional hazards regression models. Results. 463 patients were included. 43.0% received VKAs, 16.6% received NOACs, and 40.4% received APT. Over a median of 468 days’ follow‐up, NOACs group was more likely to have the thrombus resolved within 12 months’ follow‐up than VKAs (HR 2.28, 95% CI 1.57 to 3.31) or APT (HR 2.92, 95% CI 1.97 to 4.33). After adjustment for baseline variables, the significance remained in the comparison of NOACs versus VKAs (HR 2.13, 95% CI 1.41 to 3.22) as well as NOACs versus APT (HR 2.55, 95% CI 1.53 to 4.27). No significant differences were identified in bleeding rate, thromboembolism rate, or all‐cause death in 12 months’ follow‐up. Conclusion. Our findings showed that patients who were male, diagnosed with MI with or without ventricular aneurysm, or diagnosed with coronary artery diseases medical history had a risk of thrombus unresolved. Patients with NOACs had a higher resolution and a similar safety profile comparing VKAs or APT, which persisted after adjusting for other factors. Large randomized controlled trials are required urgently. This trial is registered with NCT05006677.

19 August 2025 in Pharmacological Research
Verified
Journal Article
Open access
SFShenghui Feng
Shenghui Feng
YZYue Zhou
Yue Zhou
LGLinjuan Guo
Linjuan Guo
YLYan Liang
Yan Liang
WZWengen Zhu
Wengen Zhu
Cardiometabolic diseases (CMDs), encompassing both cardiovascular diseases and metabolic syndromes, are among the leading causes of global morbidity and mortality. Protein S-palmitoylation, a reversible lipid-based post-translational modification, has emerged as a crucial regulator of cellular function and homeostasis. Palmitoylation is catalysed by palmitoyl transferases (PATs), also known as ZDHHC (zinc finger Asp-His-His-Cys) proteins, while a series of deacylases mediate the process of depalmitoylation. By modulating protein hydrophobicity, stability, subcellular localization, enzymatic activity, and membrane trafficking, palmitoylation exerts profound effects on cellular function. Physiologically, maintaining normal palmitoylation-depalmitoylation cycle are crucial in regulating the activity and membrane localization of ion channels involved in cardiomyocyte electrophysiology, modulating endothelial metabolism, cell-cell interactions, and repair following vascular injury, as well as influencing insulin signalling in cardiomyocyte metabolism. In the aspect of pathogenesis, palmitoylation influences the development of CMDs such as coronary artery disease (CAD), heart failure (HF), hypertension, type 2 diabetes (T2D), diabetic cardiomyopathy (DbCM), obesity, and non-alcoholic fatty liver disease (NAFLD). Dysregulation of the palmitoylation-depalmitoylation cycle contributes to these pathological processes, exacerbating disease progression. This review systematically explores the biological functions of palmitoylation in cardiometabolic physiology and diseases, discussing potential therapeutic targets within the palmitoylation pathway. By maintaining normal palmitoylation-depalmitoylation cycle and preventing its dysregulation, novel strategies for the prevention and treatment of CMDs may be developed.